These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 23443308)
41. Drug resistance modulation in the laboratory and the clinic. Dalton WS Semin Oncol; 1993 Feb; 20(1):64-9. PubMed ID: 8475411 [No Abstract] [Full Text] [Related]
43. [Treatment of children and adolecents with cancer after the application of the guide lines for good clinical practice in 2004 and the evaluation of new measurements]. Göbel U; Körholz D; Bernig T; Niehues T; Klingebiel T; Eggert A Klin Padiatr; 2012 Oct; 224(6):335-8. PubMed ID: 23143760 [No Abstract] [Full Text] [Related]
44. Tumor-initiating cells and treatment resistance: how goes the war? Lewis MT; Wicha MS J Mammary Gland Biol Neoplasia; 2009 Mar; 14(1):1-2. PubMed ID: 19238526 [No Abstract] [Full Text] [Related]
45. Tumor chemosensitization by physical exercise? Insights from an anidmal model. Vaccarezza M; Vitale M Future Oncol; 2015; 11(6):885-7. PubMed ID: 25760967 [No Abstract] [Full Text] [Related]
46. Tumor physiology and resistance to chemotherapy: repopulation and drug penetration. Davis AJ; Tannock IF Cancer Treat Res; 2002; 112():1-26. PubMed ID: 12481709 [No Abstract] [Full Text] [Related]
47. Breakthrough in cancer treatment. van der Linde I S Afr Med J; 1998 Jul; 88(7):813. PubMed ID: 9698707 [No Abstract] [Full Text] [Related]
48. Emerging Trends in Cancer Drug Discovery-From Drugging the "Undruggable" to Overcoming Resistance. Rudolph J; Settleman J; Malek S Cancer Discov; 2021 Apr; 11(4):815-821. PubMed ID: 33811118 [TBL] [Abstract][Full Text] [Related]
49. Pyroptosis in combinatorial treatment to improve cancer patients' outcome, is that what we want? Pezuk JA EBioMedicine; 2019 Mar; 41():17-18. PubMed ID: 30879924 [No Abstract] [Full Text] [Related]
50. Selected Articles from This Issue. Clin Cancer Res; 2020 Jun; 26(11):2437. PubMed ID: 32482655 [No Abstract] [Full Text] [Related]
51. Continuation or reintroduction of an antineoplastic strategy after documented disease progression. Markman M Oncology; 2013; 85(6):348-9. PubMed ID: 24335354 [No Abstract] [Full Text] [Related]
54. Implications of cancer evolution for drug development. Turajlic S; Swanton C Nat Rev Drug Discov; 2017 Jul; 16(7):441-442. PubMed ID: 28450743 [No Abstract] [Full Text] [Related]
55. Tumour response, correlates of survival and clinical benefit. Hutchinson L Nat Rev Clin Oncol; 2015 Aug; 12(8):433. PubMed ID: 26220355 [No Abstract] [Full Text] [Related]
56. Nonheritable cellular variability accelerates the evolutionary processes of cancer. Frank SA; Rosner MR PLoS Biol; 2012; 10(4):e1001296. PubMed ID: 22509130 [TBL] [Abstract][Full Text] [Related]
57. Overcoming drug resistance in cancer. Madukwe JC Cell; 2023 Apr; 186(8):1515-1516. PubMed ID: 37059057 [No Abstract] [Full Text] [Related]
58. Radiological assessment of tumour response to anti-cancer drugs: time to reappraise. Nygren P; Blomqvist L; Bergh J; Aström G Acta Oncol; 2008; 47(2):316-8. PubMed ID: 18210304 [No Abstract] [Full Text] [Related]
60. For cancer, seek and destroy or live and let live? André N; Pasquier E Nature; 2009 Jul; 460(7253):324. PubMed ID: 19606124 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]